Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright
At a glance
- $JSPR today−14.0%last $11.77
- Vs industry peers−13.75 pts6-peer median −0.21% · far behind
- Since Aug 18−47.7%from the first trade after the story
- 52-week range24.6% above low$9.45 – $72.60
- Cash runway~3.8 yrs$135.3M cash ÷ $3.0M/mo burn · 10-Q
- Coverage1 this week1 in 30 days · too few stories to call a pace
Nothing reported about jasper therapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
- How the stock is trading: $JSPR -13.96% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
Jasper Therapeutics ($JSPR) tumbled 13.96% to $11.77 in the latest session. Over the past month it is down 17.7%. It now sits 84% under the 52-week high of $72.60 and 25% above the year's low of $9.45, close to the bottom of its range. The year's high was 7.7 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 16, 2026), $JSPR lost $144.5M over the quarter to Sep 30, 2026 on revenue of $8.0M. Operations used $27.0M of cash over the nine months to Sep 30, 2026 — about $3.0M a month — against $135.3M in cash on Sep 30, 2026. At that pace the cash covers about 3.8 years. Total liabilities were $20.9M against $135.3M of cash on Sep 30, 2026. Figures are as filed with the SEC; the $JSPR page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Jasper Therapeutics, published this week. It reads neutral.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $JSPR page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. Wook AI, at the top of the page, can work out how far $JSPR is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 18, 2026. $JSPR has moved -47.69% ($22.50 to $11.77). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
